ArticleEuropean journal of nuclear medicine and molecular imaging2017
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Pooled it
- Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.Medicine · 2020Pooled it
- Third-line treatment andEuropean journal of nuclear medicine and molecular imaging · 2018Pooled it
- Trial
- Overall Survival with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Refining the clinical utility of [European journal of nuclear medicine and molecular imaging · 2026Article
- Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026Article
- Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers.Diagnostics (Basel, Switzerland) · 2025Review
- A Case Report on the Dramatic Response ofCurrent medical imaging · 2025Article
- Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer.Cancers · 2024Review
- Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer-A case report.Frontiers in medicine · 2024Article
- Article
- Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Review
- Biodistribution and dosimetry for combined [European journal of nuclear medicine and molecular imaging · 2023Article
- Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.European journal of radiology open · 2023Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUp to 30% of patients with castration-resistant prostate cancer (CRPC) do not show any response to the first cycle of radioligand therapy (RLT) with [
methodsCRPC patients were treated with Lu-PSMA, with a median interval of 8 weeks between each cycle. The tumour marker prostate-specific antigen (PSA) was used as the marker for response evaluation.
resultsFifty-two patients underwent a total of 190 cycles of RLT (3-6 cycles per patient). Of these, 80.8% showed a decline in PSA 2 months after the first cycle, with 44.2% showing a PSA decline of ≥50%. When compared to baseline PSA, 73.1% showed a PSA decline after the third cycle. 50% of patients that did not show any response to the first cycle also did not respond to the second and third cycles. The median OS was 60 weeks in all patients. The median OS was significantly longer for patients that showed any PSA decline after the first cycle compared to patients without PSA decline (68 vs. 33 weeks). There was a significant difference in median OS between responders and non-responders for a change in PSA after the third cycle compared to baseline PSA.
conclusionPatients with a positive response to RLT, regardless of the rate of decline, had a significantly longer median OS. Of the patients that did not show any response to the first cycle, 50% responded to the second or third cycles.
Indexed as
Identifiers
28488028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.